{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:27:55Z","timestamp":1789820875603,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There are large variations in how individual patients respond to allergen immunotherapy (AIT) against grass and\/or birch allergy. There are currently no reliable biomarkers to predict which patients are likely to benefit from the treatment. The purpose of this study was to examine the potential of cytokine and soluble immunologic checkpoint molecule (ICM) levels as biomarkers for AIT success. Blood samples collected before starting AIT were analyzed for concentration of 92 different cytokines and 14 different ICMs. Traditional univariable statistical analysis was performed to evaluate differences between responders and non-responders. Furthermore, both unsupervised and supervised machine learning algorithms were used for multivariable analysis of differences between the responders and non-responders and to try to identify clusters within the subjects which could potentially be linked to endotypes of allergic rhinitis. Neither univariable nor multivariable analysis showed any significant correlations between AIT outcome and pre-treatment levels of cytokines or soluble ICM. In the cluster analysis, 4 clustering algorithms consistently grouped 48 of the 60 subjects into 3 distinct clusters. However, these clusters did not correlate with clinical characteristics, indicating that the clusters are unlikely to represent actual biological endotypes. The findings of this study did not provide evidence supporting the use of pre-treatment levels of cytokines and ICM as biomarkers for AIT outcome.<\/jats:p>","DOI":"10.1038\/s41598-026-53894-6","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:44:40Z","timestamp":1779140680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytokines and immunologic checkpoint molecules in predicting success of allergen immunotherapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Martin","family":"Berge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Hultgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svante","family":"Hugosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanj","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"53894_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13601-017-0157-8","volume":"7","author":"G De Greve","year":"2017","unstructured":"De Greve, G. et al. Endotype-driven treatment in chronic upper airway diseases. Clin. Transl. Allergy 7, 22 (2017).","journal-title":"Clin. Transl. Allergy"},{"key":"53894_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4168\/aair.2016.8.3.191","volume":"8","author":"M Jutel","year":"2016","unstructured":"Jutel, M., Kosowska, A. & Smolinska, S. Allergen immunotherapy: Past, present, and future. Allergy Asthma Immunol. Res. 8, 191\u2013197 (2016).","journal-title":"Allergy Asthma Immunol. Res."},{"key":"53894_CR3","unstructured":"ARIA Guideline 2019: Treatment of Allergic Rhinitis in the German Health System\u2014PMC. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7066682\/."},{"key":"53894_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/all.13350","volume":"73","author":"C Rond\u00f3n","year":"2018","unstructured":"Rond\u00f3n, C. et al. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy 73, 905\u2013915 (2018).","journal-title":"Allergy"},{"key":"53894_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4168\/aair.2018.10.1.18","volume":"10","author":"JH Lee","year":"2018","unstructured":"Lee, J. H. et al. A retrospective study of clinical response predictors in subcutaneous allergen immunotherapy with house dust mites for allergic rhinitis. Allergy Asthma Immunol. Res. 10, 18\u201324 (2018).","journal-title":"Allergy Asthma Immunol. Res."},{"key":"53894_CR6","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.199","volume":"54","author":"M Berge","year":"2022","unstructured":"Berge, M., Bertilsson, L., Hultgren, O., Hugosson, S. & Saber, A. Pre-treatment allergen-specific IgE analysis and outcomes of allergen immunotherapy. Eur. Ann. Allergy Clin. Immunol. 54, 218 (2022).","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"53894_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107125","volume":"210","author":"Z Diamant","year":"2023","unstructured":"Diamant, Z., van Maaren, M., Muraro, A., Jesenak, M. & Striz, I. Allergen immunotherapy for allergic asthma: The future seems bright. Respir. Med. 210, 107125 (2023).","journal-title":"Respir. Med."},{"key":"53894_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11882-014-0435-7","volume":"14","author":"G Scadding","year":"2014","unstructured":"Scadding, G. Cytokine profiles in allergic rhinitis. Curr. Allergy Asthma Rep. 14, 435 (2014).","journal-title":"Curr. Allergy Asthma Rep."},{"key":"53894_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111898","volume":"22","author":"MA Galv\u00e1n Morales","year":"2021","unstructured":"Galv\u00e1n Morales, M. A., Montero-Vargas, J. M., Vizuet-de-Rueda, J. C. & Teran, L. M. New insights into the role of PD-1 and its ligands in allergic disease. Int. J. Mol. Sci. 22, 11898 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"53894_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31757-z","volume":"8","author":"S Rosskopf","year":"2018","unstructured":"Rosskopf, S., Jahn-Schmid, B., Schmetterer, K. G., Zlabinger, G. J. & Steinberger, P. PD-1 has a unique capacity to inhibit allergen-specific human CD4+ T cell responses. Sci. Rep. 8, 13543 (2018).","journal-title":"Sci. Rep."},{"key":"53894_CR11","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/all.13138","volume":"72","author":"MH Shamji","year":"2017","unstructured":"Shamji, M. H. et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: An EAACI position paper. Allergy 72, 1156\u20131173 (2017).","journal-title":"Allergy"},{"key":"53894_CR12","first-page":"43","volume":"27","author":"N Bayar Muluk","year":"2023","unstructured":"Bayar Muluk, N. & Cingi, C. Biologics in allergic rhinitis. Eur. Rev. Med. Pharmacol. Sci. 27, 43\u201352 (2023).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"53894_CR13","doi-asserted-by":"publisher","first-page":"1019255","DOI":"10.3389\/falgy.2022.1019255","volume":"3","author":"A Atanasio","year":"2022","unstructured":"Atanasio, A., Orengo, J. M., Sleeman, M. A. & Stahl, N. Biologics as novel therapeutics for the treatment of allergy: Challenges and opportunities. Front. Allergy 3, 1019255 (2022).","journal-title":"Front. Allergy"},{"key":"53894_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4274\/balkanmedj.galenos.2024.2024-6-19","volume":"41","author":"Z H\u0131zl\u0131 Demirkale","year":"2024","unstructured":"H\u0131zl\u0131 Demirkale, Z. et al. Comparison of immune checkpoint molecule expression in different years of house dust mite subcutaneous immunotherapy on CD4+ T and Treg cells in children with allergic rhinitis. Balkan Med. J. 41, 387\u2013395. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2024.2024-6-19 (2024).","journal-title":"Balkan Med. J."},{"key":"53894_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12016-020-08787-5","volume":"60","author":"TB Mersha","year":"2021","unstructured":"Mersha, T. B. et al. Resolving clinical phenotypes into endotypes in allergy: Molecular and omics approaches. Clin. Rev. Allergy Immunol. 60, 200\u2013219 (2021).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"53894_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/JIR.S350003","volume":"15","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Multiple-cytokine profiling: A novel method for early prediction of the efficacy of sublingual immunotherapy in allergic rhinitis patients. J. Inflamm. Res. 15, 603\u2013612 (2022).","journal-title":"J. Inflamm. Res."},{"key":"53894_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"DE Ho","year":"2011","unstructured":"Ho, D. E., Imai, K., King, G. & Stuart, E. A. MatchIt: Nonparametric preprocessing for parametric causal inference. J. Stat. Softw. 42, 1\u201328 (2011).","journal-title":"J. Stat. Softw."},{"key":"53894_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9, e95192 (2014).","journal-title":"PLoS ONE"},{"key":"53894_CR19","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2020)."},{"key":"53894_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jaci.2021.06.011","volume":"148","author":"RG van Wijk","year":"2021","unstructured":"van Wijk, R. G. & Smits, H. H. Heterogeneity in allergic rhinitis: Explained by inducible mechanistic traits?. J. Allergy Clin. Immunol. 148, 358\u2013360 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"53894_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41577-019-0131-x","volume":"19","author":"G Altan-Bonnet","year":"2019","unstructured":"Altan-Bonnet, G. & Mukherjee, R. Cytokine-mediated communication: A quantitative appraisal of immune complexity. Nat. Rev. Immunol. 19, 205\u2013217 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"53894_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/3217261","volume":"2023","author":"Y Jiang","year":"2023","unstructured":"Jiang, Y., Hu, W., Cai, Z., Lin, C. & Ye, S. Peripheral multiple cytokine profiles identified CD39 as a novel biomarker for diagnosis and reflecting disease severity in allergic rhinitis patients. Mediators Inflamm. 2023, e3217261 (2023).","journal-title":"Mediators Inflamm."},{"key":"53894_CR23","unstructured":"FAQ. Olink\u00ae https:\/\/olink.com\/knowledge\/faq."},{"key":"53894_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s40425-019-0810-y","volume":"7","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. J. Immunother. Cancer 7, 334 (2019).","journal-title":"J. Immunother. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53894-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53894-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53894-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:53:43Z","timestamp":1779141223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53894-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53894"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53894-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15356"}}